Single-Donor Fecal Transplant Trial for IBS Shows Lasting Response
-
Fecal microbiota transplantation (FMT) resulted in sustained high response rates in patients with irritable bowel syndrome (IBS) and resulted in only mild side effects after 3 years, new data show. Nearly three out of four people in a clinical trial experienced fewer symptoms and fatigue and a greater quality of life at both 2 years and 3 years after FMT, in Norway. Those FMT-treated patients who relapsed subsequently responded to FMT upon retransplantation, report the authors, who also correlated individual microbial profiles with clinical outcomes.
-
@preyashi The new study included 125 patients (104 women, 21 men) in three groups: 38 received a placebo, 42 received 30 g of donor feces, and 45 received 60 g of donor feces. The feces — all from one male donor — was administered to the duodenum. The response rates for those who received FMT were significantly higher than for those who received placebo. Those receiving 30 g of feces had a response rate of 69.1%, and those in the 60-g group had a response rate of 77.8%, whereas the response rate in the placebo group was 26.3%.